Phase Ib Open-Label Study of Loncastuximab Tesirine in Combination With Other Anticancer Agents in Patients With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma (LOTIS-7)

被引：0

作者：

Hess, Brian ^{[1
]}

Solh, Melhem ^{[2
]}

Gandhi, Mitul ^{[3
]}

Wang, Ying ^{[4
]}

Qin, Yajuan ^{[4
]}

Zinzani, Pier Luigi ^{[5
]}

Collins, Graham ^{[6
]}

机构：

[1] Med Univ South Carolina, Div Hematol & Med Oncol, Dept Med, Charleston, SC USA

[2] Blood & Marrow Transplant Grp Georgia, Atlanta, GA USA

[3] Virginia Canc Specialists, Fairfax, VA USA

[4] ADC Therapeut Amer, Murray Hill, NJ USA

[5] Univ Bologna, Inst Hematol Seragnoli, Bologna, Italy

[6] Oxford Univ Hosp NHS Trust, Oxford, England

来源：

关键词：

non-Hodgkin lymphoma; loncastuximab tesirine; polatuzumab vedotin; glofitamab; mosunetuzumab; trial-in-progress;

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

ABCL-134

引用

页码：S419 / S420

页数：2